Amplia Therapeutics has reshaped its board as it moves toward the next phase of its cancer-drug development program. Multiple outlets report that the company hands the chairman’s role to Jane Bell AM, indicating a leadership change timed to upcoming regulatory and clinical developments. The board update comes as Amplia prepares for continued work following pancreatic cancer trial results and as progress continues with US regulatory processes. The reports describe the change as part of planning for the next stage of the drug push, with management positioning the company to respond to both ongoing trial outcomes and potential regulatory milestones in the United States. While the coverage focuses on governance and timing, it does not specify additional board members or detailed clinical endpoints in the provided summaries. Overall, the outlets agree on the main elements: a new chair is appointed, pancreatic cancer trial results are a key context for the transition, and US regulatory progress is central to the company’s preparations for the next development step.